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Rabies is a viral zoonotic infection of
the central nervous system caused by a
lyssavirus. The disease is fatal without
proper post exposure prophylaxis (PEP).
In July 1885, Louis Pasteur obtained his
first success against rabies by vaccinating
Joseph Meister, a 9-year-old boy present-
ing with multiple deep bite wounds [1].
After more than 700 successful inocula-
tions, Pasteur launched an international
subscription and opened the world’s first
research institute dedicated to the preven-
tion of rabies and other infectious diseases.
The Institut Pasteur was born. Due to
substantial advances during the 20th
century, safe and effective human and
animal vaccines based on tissue culture
methodologies are available today. Today,
125 years later, Institut Pasteur is at the
core of an international network of 30
institutes. Through its numerous institu-
tions established in enzootic areas, the
worldwide contribution of the Institut
Pasteur International Network to rabies
surveillance and control is still of para-
mount importance. Each year, the Inter-
national Network is responsible for PEP
administration to more than 180,000
exposed patients, mainly in Southeast Asia
and Africa. Scientists and health staff are
also involved in various national commit-
tees that work on the development and
successful implementation of rabies con-
trol programs.
Sadly, whereas extensive efforts in
developed countries have largely con-
trolled dog (the United States and Europe)
and fox (western and central Europe)
rabies [2,3], dog rabies remains enzootic
in much of the world, and 15 million
people require PEP every year. Rabies is
considered one of the most neglected
diseases in the world’s developing coun-
tries with the greatest burden in poor rural
communities, and disproportionately in
children. According to the World Health
Organization (WHO), 30% to 50% of the
55,000 victims estimated each year are
individuals under 15 years of age [4]. Over
95% of these human rabies cases are
concentrated in Asia (especially in India)
and Africa, and 99% of them are trans-
mitted by dogs. There are several reasons
for the lack of accurate data, including
weak or non-existent rabies surveillance
systems; under-reporting of cases by local
communities and central authorities; un-
reliable diagnosis of cases, which is
generally based on clinical criteria rather
than laboratory confirmation; and inade-
quate legislation for compulsory notifica-
tion of cases. The absence of accurate data
on disease burden, upon which regional
and national priorities for research and
control are based, leads to a vicious cycle
of indifference and neglect [5].
The question now is why, despite the
availability of safe and effective human
vaccines, human rabies deaths continue to
escalate in many parts of the world. There
are several general and specific explana-
tions for the continued burden of dog
rabies [6–8].
In general, there is a lack of awareness
amongst policy-makers of the rabies bur-
den and impacts and the need for
prioritizing resources towards its control.
Further, despite the widely advocated
need for intersectoral collaboration be-
tween government ministries, the recogni-
tion of roles and responsibilities amongst
agencies as well as integration of budgets
across ministries still poses considerable
challenges.
Mass vaccination of dogs is the most
cost-effective way to achieve a significant
and lasting reduction in the number of
human deaths from rabies [9]. However,
such prevention efforts are often not
prioritized by national governments in
even the most endemic countries. Among
the reasons for the low priority afforded
rabies are, as for many neglected tropical
diseases, its predominance in remote rural
areas and its disproportionate impact on
people living in extreme poverty. There-
fore, lack of resources, gaps in epidemio-
logical knowledge (e.g., level of vaccina-
tion coverage needed in any given setting),
lack of in-country expertise on implemen-
tation of canine rabies control strategies,
and sustainability issues impair the success
of such programs.
Additionally, in most developing coun-
tries (with some notable exceptions), there
is a lack of awareness among the popula-
tion, including medical practitioners and
health authorities, about the widespread
extent of the disease and the risk of
transmission from dogs to human popula-
tions [6–8]. Additionally, the infrastruc-
ture for the management of rabies expo-
sure is scarce. Many people who are
exposed to rabies do not seek PEP,
because they are not aware of the risk of
contracting this disease or because they
live in rural areas too far away from rabies
prevention centers, which are generally
located in big cities. In some cases, the
world’s poorest people simply cannot
afford the cost of PEP.
A range of key scientific questions also
remains unsolved, and there is an urgency
to promote research and development on
the fundamental aspects of rabies molec-
ular pathobiology, improved control tools,
and operational research. There is also a
need for multidisciplinary integrative ap-
proaches that rely on the following
elements.
1. It is essential to find ways to improve
epidemiological surveillance using di-
agnostic approaches to rabies based on
validated protocols and specimens and
evaluated under field conditions [10–
12]. Epidemiological models are also
needed to better estimate the inci-
dence of rabies [4,13,14]. Recent
research on this topic published in this
journal yielded rabies incidence for
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[15].
2. Information concerning the epidemiolo-
gy and population dynamics of rabies in
its natural animal host population,
particularly dogs (involved in more than
99% of human fatalities), is lacking.
Understanding the ecological patterns,
frequency, and extent of movement of
virally infected animals is of paramount
importance in predicting the spread of
zoonotic infections [16,17], and hence is
essential for their ultimate control. Also,
work on dog population studies and their
accessibility to vaccination is still needed.
Some recent epidemiological studies
have made advances in this area
[14,18–21]. Further, extensive genomic
and evolutionary analyses establishing
the diversity of lyssavirus species and
variants will help us to better understand
the determinants of rabies spread. The
analysis of integrated phylogeographic
data can now transform viral genetic
data into a powerful asset for character-
izing, predicting, and potentially control-
ling the spatial spread of rabies and,
more largely, of pathogens [22–24].
Understanding the conditions under
which the containment of dog rabies
can reliably be achieved will facilitate the
long-term goal of its elimination.
3. Cheaper and innovative therapeutic
approaches are urgently required. Cur-
rently, the recommended treatment for
individuals exposed to rabies virus is
the combined administration of rabies
vaccine and immunoglobulins [25,26].
Both of these biologics remain relative-
ly expensive for a significant portion of
the target population. The average cost
per rabies vaccination, which is the
sum of direct and indirect costs with
vaccine application alone, is US$45 in
Africa and Asia (whereas the average
salary is often less than US$2 per day in
most endemic countries). When rabies
immunoglobulins are also provided,
the cost is around US$100 per patient
[4]. Therefore, it is necessary to search
for ways and means to decrease the
cost of rabies biologicals. Recently,
efforts to develop new generation
biologics comprised of mixtures of
human anti-rabies monoclonal anti-
bodies have yielded promising results
[27]. Antiviral therapy to treat rabid
patients is also lacking. Exploring
innovative therapeutic approaches
based on blocking interactions among
viral proteins will probably lead to the
discovery and development of new
small molecule compounds [28–30].
Although tools for successful dog rabies
control are available, and other factors
are responsible for the failure to bring
dog rabies under control in most of the
developing world [20], present efforts
in translational and operational re-
search on innovative veterinary vac-
cines and modes of delivery will have to
be continued in order to provide better
and easier control of the animal
reservoir in tropical and resource-poor
conditions [31–34].
4. A comprehensive understanding of the
pathobiology of rabies viruses is lack-
ing. Many studies are now addressing
the nature of the relationships among
lyssaviruses and their hosts [35–37],
but the respective role of different viral
proteins and how they affect the host
cellular machinery remains largely a
mystery [38–40]. An analysis compar-
ing the pathogenic processes in differ-
ent lyssaviruses found in nature with
different human susceptibilities could
be central to answering this question.
In conclusion, we strongly recommend
the establishment of a comprehensive
national rabies control program in each
of the world’s enzootic countries to ensure
continued political commitment and ac-
tive community participation. Also, once
established, international support will have
to be provided to implement and sustain
rabies control activities. The universal
establishment of national programs could
also help to ensure that only WHO-
recommended rabies vaccines are admin-
istered and made available to local popu-
lations, and that dog rabies transmission is
controlled and ultimately eliminated or
eradicated. Since 2007, World Rabies Day
(http://www.worldrabiesday.org/) has
been held every September 28th (the day
of Louis Pasteur’s death). This commem-
oration is an invaluable advocacy tool for
increasing awareness in local populations,
informing them about the effects of the
disease in humans and animals, promoting
existing preventive measures, and ulti-
mately eradicating human rabies by fo-
cusing on the control of animal reservoirs.
The legacy of Louis Pasteur reminds us
that despite rapidly shifting priorities due to
periodic recognition of emerging diseases,
none of these other conditions exceeds the
case fatality rate of rabies. Substantive
coordinated efforts towards building and
strengthening medical, veterinarian, scien-
tific, and research capacities towards rabies
control must be made. This comprehensive
and intersectoral approach requires an
increasing involvement of philanthropic
organizations, government funding agen-
cies, and public–private partnerships to
promote political awareness and expand
funding opportunities. Through its numer-
ous research, development, and public
health activities, the Institut Pasteur Inter-
national Network continues its 125-year-
long commitment to fight this deadly
disease. Together with local scientific
institutes and vaccine and other biologics
manufacturers, the WHO and its regional
offices, the World Organization for Animal
Health, the Food and Agriculture Organi-
zation, and the affected communities them-
selves, the Institut Pasteur wishes to com-
memorate this anniversary by supporting
coalitions of world partners that have come
together to improve rabies prevention
capacities in developing countries, and to
eliminate this ancient scourge. The mem-
bers of the Institut Pasteur International
Network, together with national reference
centers and WHO Collaborating Centers,
are working actively to develop specific
multidisciplinary strategies that promote
many of the existing coalitions already
committed to rabies (e.g., Alliance for
Rabies Control with initiatives including
Partners for Rabies Prevention, World
Rabies Day, and the Blueprint for Rabies
Prevention and Control). When imple-
mented globally, these strategies will ulti-
mately improve our understanding of the
distribution of the disease, the resulting
immunological consequences, and the de-
velopment of new diagnostic techniques,
drugs, and vaccines.
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